BCLS II Investco, LP

SEC CIK: 0001818893

SEC filings (opens in a new tab)

No open-market purchases or sales filed in the past year.

Current role at each company

SLDB Solid Biosciences Inc.10% Owneras of Feb 21, 2025
NAMS NewAmsterdam Pharma Co N.V.10% Owneras of Dec 17, 2024
XLO Xilio Therapeutics, Inc.10% Owneras of Dec 10, 2021

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought: –; 0 filings
Sold: –; 0 filings
Net: –; Bought minus sold
Companies: 0; With open-market trades

Trades

Every Form 4 that lists BCLS II Investco, LP as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

Transaction type

Role

Minimum value (USD)

Filed from

Filed to

Filing delay at least (days)

Filing delay at most (days)

SLDB Solid Biosciences Inc.

10% Owner2 trades

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Feb 21, 2025 (view filing)5:48 PM ET	Feb 19	2 days	BCIP Life Sciences Associates, LP and 9 others10% Owner	PPurchase	+1.00M	$4.03	+$4.03M	+24.8%5.03M after
Feb 21, 2025 (view filing)5:48 PM ET	Feb 19	2 days	BCIP Life Sciences Associates, LP and 9 others10% Owner	PPurchase	+6.44M	$4.03	+$26.0M	–6.44M after	Derivative

NAMS NewAmsterdam Pharma Co N.V.

10% Owner1 trade

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Dec 17, 2024 (view filing)5:05 PM ET	Dec 13	4 days	BCIP Life Sciences Associates, LP and 9 others10% Owner	PPurchase	+1.63M	$24.50	+$40.0M	–1.63M after	Derivative

XLO Xilio Therapeutics, Inc.